New Research from the CWMH: Data on the Reproductive Safety of Vortioxetine
New prospective data on 56 first-trimester vortioxetine exposures found no major malformations, offering reassuring but still preliminary reproductive safety information.
New prospective data on 56 first-trimester vortioxetine exposures found no major malformations, offering reassuring but still preliminary reproductive safety information.
As women transition into the menopause, they experience a constellation of symptoms including vasomotor symptoms (hot flashes and night sweats), sleep disruption, problems with sexual functioning, and cognitive impairment. Women may also be more [...]